Journal of Periodontal and Implant Science

Korean Academy of Periodontology (대한치주과학회)
권호 표지

The effect of five osteotropic factors on osteoprotegerin mRNA expression in gingival fibroblasts

  • Ko, Young-Kyung (Department of Dentistry, College of Medicine, The Catholic University of Korea)
  • Published : 2008.08.15
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: Osteoprotegerin (OPG) is a secreted glycoprotein and a member of the tumor necrosis factor (TNF) receptor family that inhibits bone resorption by suppressing osteoclastogenesis. Gingival fibroblasts (GF) play a role in periodontal disease progression, and the purpose of this experiment was to evaluate influence of osteotropic factors on the expression of osteoprotegerin mRNA in these cells. Materials and Methods: In this experiment, the influence of osteoclastogenic factors, interleukin-1 beta (IL-$1{\beta}$), TNF-$\alpha$, prostanglandin E2 ($PEG_2$). parathyroid hormone (PTH) and 1$\alpha$, 25-dihydroxyvitamin $D_3$ on the expression of osteoprotegerin mRNA in GF was studied by Northern blot hybridization. Results: As expected, $PEG_2$ tended to inhibit OPG levels and this was most prominent at 24 hours of culture with $10^{-7}M$ of $PEG_2$. TNF-$\alpha$ at 10ng/ml and also at 25ng/ml decreased OPG levels to almost 30% of the control at 24 hours. This contrasts with reports of increased OPG levels from osteoblast/stromal cells and gingival fibroblasts stimulated by TNF-$\alpha$. Decrease of OPG levels with $PEG_2$ and TNF-$\alpha$ suggests a pathway whereby these mediators exert their resorptive effects. However, OPG levels were increased almost 3-fold at 24 hours with IL-1$\beta$(1 to 15ng/ml) and increased 1.4 fold with 24-hour treatment of $10^{-7}M$ PTH. Conclusion: Increase of OPG levels suggests that these 'osteoclastogenic' factors act in more complex ways and may act to inhibit bone resorption in inflammatory periodontitis. This result supports the role of OPG as a negative feedback mechanism in osteoclastic activity.

Keywords

References

  1. Udagawa N, Takahashi N, Akatsu T, et al. The bone marrow-derived stromal cell lines MC3T3-G2/PA6 and ST2 support osteoclast-like cell differentiation in cocultures with mouse spleen cells. Endocrinology 1989;125:1805-1813. https://doi.org/10.1210/endo-125-4-1805
  2. Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis inhibitory factor and is identical to TRANCE/ RANKL. Proc Natl Acad Scie USA 1997;95:3597-3602.
  3. Anderson D, Marakovsky E, Billingsley W, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell fuction. Nature 1997;390:175-179. https://doi.org/10.1038/36593
  4. Lacey DL, Timms E, Tan H, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-176. https://doi.org/10.1016/S0092-8674(00)81569-X
  5. Wong B, Rho J, Arron J, et al. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem 1997;272: 25190-25194. https://doi.org/10.1074/jbc.272.40.25190
  6. Takayanagi T. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nature Reviews Immunology 2007;7:292-305. https://doi.org/10.1038/nri2062
  7. Nakagawa N, Kinosaki M, Yamaguch et al. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun 1998;253:395-400. https://doi.org/10.1006/bbrc.1998.9788
  8. Yamashita T, Yao Z, Li F et al. NF-κB p50 and p52 Regulate Receptor Activator of NF-κB Ligand (RANKL) and Tumor Necrosis Factor-induced osteoclast precursor differentiation by activating c-Fos and NFATc1. J Biol Chem 2007;282:18245-18253. https://doi.org/10.1074/jbc.M610701200
  9. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-319. https://doi.org/10.1016/S0092-8674(00)80209-3
  10. Hofbauer LC, Gori F, Riggs BL, et al. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 1999;140:4382-4389. https://doi.org/10.1210/en.140.10.4382
  11. Hofbauer LC, Schoppet M. Clinical Implications of the Osteoprotegerin/RANKL/RANK system for bone and vascular Diseases. JAMA 2004;292:490-495. https://doi.org/10.1001/jama.292.4.490
  12. Theoleyre S, Wittrant Y, Kwan Tat S et al. Y, The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine & Growth Factor Reviews 2004;15:457-475. https://doi.org/10.1016/j.cytogfr.2004.06.004
  13. Sakata M, Shiba H, Komatzuzawa H et al. Expression of osteoprotegerin (osteoclastogenesis inhibitory factor) in cultures of human dental mesenchymal cells and epithelial cells. J Bone Min Res 1999;14:1486-1492. https://doi.org/10.1359/jbmr.1999.14.9.1486
  14. Mundy GR. Inflammatory mediators and the destruction of bone. J Periodont Res 1991;26: 213-217. https://doi.org/10.1111/j.1600-0765.1991.tb01647.x
  15. Yasuda H, Shima N, Nakagawa N, et al. Identity of osteoclastogenesis inhibitory factor(OCIF) and osteoprotegerin(OPG); A mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 1998;139:1329-1337. https://doi.org/10.1210/en.139.3.1329
  16. Rani SCS, MacDougall, M. Dental cells express factors that regulate bone resorption. Molecular Cell Biol Res Comm 2000;3:145-152. https://doi.org/10.1006/mcbr.2000.0205
  17. Wada N, Maeda H, Tanabe K, et al. Periodontal ligamental cells secrete the factor that inhibits osteoclastic differentiation and function: the factor is osteoprotegerin/osteoclastogenesis inhibitory factor. J Periodontal Res 2001;36:56-63. https://doi.org/10.1034/j.1600-0765.2001.00604.x
  18. Teng YTA, Nguyen H, Xuijuan G, et al. Functional T-cell immunity and osteoprotegerin control alveolar bone destruction in periodontal infection. J Clin Invest. 2000;106:R59-R67. https://doi.org/10.1172/JCI10763
  19. Tokoro Y, Yamamoto T, Hara K. IL-1beta mRNA as the predominant inflammatory cytokine transcript:correlation with inflammatory cell infiltration into human gingival. J Oral Pathol Med 1996;25:225-231. https://doi.org/10.1111/j.1600-0714.1996.tb01376.x
  20. Stashenko P, Dewhirst FE, Peros WJ, Kent RL, Ago JM. Synergistic interactions between interleukin-1, tumor necrosis factor and lymphotoxin in bone resorption. J Immunol 1987;138:1464-1468.
  21. Matsuki Y, Yamamoto T, Hara K. Localization of interleukin-1 mRNA expressing macrophages in human inflamed gingiva and IL-1 activity in gingival crevicular fluid. J Periodontal Res 1993;28:35-42. https://doi.org/10.1111/j.1600-0765.1993.tb01048.x
  22. Koide M, Suda S, Saitoh S, et al. In vivo administration of IL-1 beta accelerates silk ligature-induced alveolar bone loss. J Oral Pathol Med 1995;24:420-434. https://doi.org/10.1111/j.1600-0714.1995.tb01212.x
  23. Nakashima T, Kobayashi Y, Yamasaki S, et al. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines. Biochem Biophys Res Commun 2000;275:768-775. https://doi.org/10.1006/bbrc.2000.3379
  24. Hofbauer LC, Dunstan CR, Spelsberg TC, Riggs BL, Khosla S. Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2 and cytokines. Biochem Biophys Res Commun 1998;250:776-781. https://doi.org/10.1006/bbrc.1998.9394
  25. O'Brien EA, Williams JH, Marshall MJ. Osteoprotegerin is produced when prostaglandin synthesis is inhibited causing osteoclasts to detach from the surface of mouse parietal bone and attach to the endocranial membrane. Bone 2001;28:208-214. https://doi.org/10.1016/S8756-3282(00)00431-2
  26. Brandstrom H, Bjorkman T, Ljunggren O. Regulation of osteoprotegerin secretion from primary cultures of human bone marrow stromal cells. Biochem Biophys Res Commun 2001;280: 831-835. https://doi.org/10.1006/bbrc.2000.4223
  27. Choi BK, Moon SY, Cha JH, Kim KW, Yoo YJ. Prostaglandin E2 is a main mediator in receptor activator of nuclear factor-kappaB ligand-dependent osteoclastogenesis induced by Porphyromonas gingivalis, Treponema denticola, and Treponema socranskii. J Periodontol 2005;76:813-20. https://doi.org/10.1902/jop.2005.76.5.813
  28. Ogata Y, Niisato N, Sakurai T, Furuyama S, Sugiya H. Comparison of the characteristics of human gingival fibroblasts and periodontal ligament cells. J Periodontol 1995;66:1025-1031. https://doi.org/10.1902/jop.1995.66.12.1025
  29. Horwood NJ, Elliott J, Martin TJ, Gillespie MT. Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. Endocrinology 1998;139:4743-4746. https://doi.org/10.1210/en.139.11.4743
  30. Wada N, Maeda H, Yoshimine Y, Akamine A. Lipopolysaccharide stimulates expression of osteoprotegerin and receptor activator of NF-kappa B ligand in periodontal ligament fibroblasts through the induction of interleukin-1 beta and tumor necrosis factor-alpha. Bone 2004;35:629-635. https://doi.org/10.1016/j.bone.2004.04.023
  31. Quinn JM, Horwood NJ, Elliott J, Gillespie MT, Martin TJ. Fibroblastic stromal cells express receptor activator of NF-&B ligand and support osteoclast differentiation. J Bone Miner Res 2000;15:1459-1466. https://doi.org/10.1359/jbmr.2000.15.8.1459
  32. Huang L, Xu J, Wood DJ, Zheng MH. Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation. Am J Pathol 2000;156:761-767. https://doi.org/10.1016/S0002-9440(10)64942-5
  33. Suda T, Ueno Y, Fujii K, Shinki T. Vitamin D and Bone. J Cell Biochem 2003;88:259-266. https://doi.org/10.1002/jcb.10331
  34. Hofbauer LC, Heufelder AE. The role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases. J Clin Endocrinol Metab 2000;85:2355-2363. https://doi.org/10.1210/jc.85.7.2355
  35. Lories RJ Luyten FP. Osteoprotegerin and osteoprotegerin-ligand balance: a new paradigm in bone metabolism providing new therapeutic targets. Clin Rheumatol 2001;20:3-9. https://doi.org/10.1007/s100670170095
  36. Bekker PJ, Holloway D, Nakanishi A, Arrighi M, Leese PT, Dunstan CR. The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 2001;16:348-360. https://doi.org/10.1359/jbmr.2001.16.2.348
  37. Bekker PJ, Holloway D, Nakanishi A, et al. The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Mineral Res Feb 2001;16:348-360. https://doi.org/10.1359/jbmr.2001.16.2.348
  38. Cohen SB, Dore RK, Lane NE, et al. Denosumab treatment effects on structural damage, I. bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 2008;59:1299-1309. https://doi.org/10.1002/art.24018